Literature DB >> 26767429

Selection of Single Chain Antibody Fragments for Targeting Prostate Specific Membrane Antigen: A Comparison Between Cell-based and Antigen-based Approach.

Javad Rezaei, Masoumeh RajabiBazl1, Walead Ebrahimizadeh, Gholamreza Rafiei Dehbidi, Hossien Hosseini.   

Abstract

Prostate cancer (PCa) is the most frequently diagnosed cancer and the second most common cause of cancer related mortality in United States male population. ScFv fragments have different usefulness. For example they have small size, high perfusion rate, high yield of production and are non-immunogenic, thus they can be used for therapeutic purposes. In this project we used a synthetic human ScFv library for isolation of ScFv monoclonal antibodies against prostate specific membrane antigen. For this purpose, after five rounds of cell-panning, and also five rounds of antigen-panning with rPSMA specific anti- PSMA ScFv-phage particles were isolated. Phages with high affinity toward PSMA were selected and used for further analysis. Specificity and affinity of both ScFv to PSMA and LnCaP cell line examined by ELISA. Recombinant ScFv antibody isolated from cell-panning had higher specificity and affinity for both the antigen and LNCaP cell line. Our result demonstrated that ScFv antibody obtained by cell-panning can target PSMA antigen and cell lines.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26767429     DOI: 10.2174/0929866523666160115131403

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  2 in total

1.  Development of a novel anti-HER2 scFv by ribosome display and in silico evaluation of its 3D structure and interaction with HER2, alone and after fusion to LAMP2B.

Authors:  Fatemeh Salimi; Mehdi Forouzandeh Moghadam; Masoumeh Rajabibazl
Journal:  Mol Biol Rep       Date:  2018-09-17       Impact factor: 2.316

2.  Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.

Authors:  Zora Novakova; Nikola Belousova; Catherine A Foss; Barbora Havlinova; Marketa Gresova; Gargi Das; Ala Lisok; Adam Prada; Marketa Barinkova; Martin Hubalek; Martin G Pomper; Cyril Barinka
Journal:  Int J Mol Sci       Date:  2020-09-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.